MAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Grb2 is a potent activator of ERK1 and ERK2 in Ph+ leukemic cells [200], and the use of BP1001, a liposome-packaged Grb2 antisense oligonucleotide is well tolerated in CML patients [201] and is evaluated in combination with Dasatinib in a phase I/II clinical trial (NCT02923986).